Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|07/09/2010||03/05/2010||A Phase II single blind, randomized, placebo controlled trial to study the efficacy and safety of anti-von Willebrand factor Nanobody administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.||A Phase II single blind, randomized, placebo controlled trial to study the efficacy and safety of anti-von Willebrand factor Nanobody administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.||Acquired thrombotic thrombocytopenic purpura (TTP) |
MedDRA version: 16.0;Level: PT;Classification code 10043648;Term: Thrombotic thrombocytopenic purpura;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
|Product Name: Anti-von Willebrand Factor Nanobody, INN = Caplacizumab|
Product Code: ALX-0081
INN or Proposed INN: Caplacizumab
Other descriptive name: Anti-von Willebrand Factor Nanobody
|Ablynx||NULL||Not Recruiting||Female: yes|
|115||Phase 2||United States;Spain;Belgium;Austria;Australia;Israel;Germany;Italy;United Kingdom;Switzerland|